Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Chinese Patent Office
Julphar
Dow
Daiichi Sankyo
Harvard Business School
Accenture
AstraZeneca
Citi

Generated: June 22, 2018

DrugPatentWatch Database Preview

ELOCON Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Elocon patents expire, and what generic alternatives are available?

Elocon is a drug marketed by Merck Sharp Dohme and is included in three NDAs.

The generic ingredient in ELOCON is mometasone furoate. There are twenty-nine drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.

US Patents and Regulatory Information for ELOCON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme ELOCON mometasone furoate CREAM;TOPICAL 019625-001 May 6, 1987 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme ELOCON mometasone furoate OINTMENT;TOPICAL 019543-001 Apr 30, 1987 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme ELOCON mometasone furoate CREAM;TOPICAL 019625-002 Apr 19, 2013 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme ELOCON mometasone furoate LOTION;TOPICAL 019796-001 Mar 30, 1989 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for ELOCON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme ELOCON mometasone furoate LOTION;TOPICAL 019796-001 Mar 30, 1989 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme ELOCON mometasone furoate CREAM;TOPICAL 019625-001 May 6, 1987 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme ELOCON mometasone furoate OINTMENT;TOPICAL 019543-001 Apr 30, 1987 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme ELOCON mometasone furoate LOTION;TOPICAL 019796-001 Mar 30, 1989 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ELOCON
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Topical Solution (Lotion) 0.10% ➤ Subscribe 2004-06-10

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Johnson and Johnson
Merck
Fuji
McKinsey
Cipla
Dow
Cantor Fitzgerald
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.